Immunocore Holdings Plc (IMCR) Stock Price & Analysis
Immunocore Holdings Plc (IMCR) rose 2.63% to USD 28.52 as of June 10, 2026 at 03:09 UTC, according to Nexqual real-time market data.
IMCR last closed at USD 27.79; the session ranged USD 28.09–29.23 on volume of 315,469 shares. Market capitalization is $1.45B, with a 52-week range of USD 27.56–40.72 (NMS). Source: Nexqual, June 10, 2026 at 03:09 UTC.
Key Statistics (as of June 10, 2026 at 03:09 UTC)
| Price | USD 28.52 |
|---|---|
| Change | ▲ 2.63% (up) |
| Previous Close | USD 27.79 |
| Open | USD 28.17 |
| Day Range | USD 28.09 – 29.23 |
| 52-Week Range | USD 27.56 – 40.72 |
| Volume | 315,469 shares |
| Market Cap | $1.45B |
| Exchange | NMS |
Technical Analysis (IMCR)
Nexqual's technical model rates IMCR "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:09 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 46.07 (neutral) |
| vs SMA50 | Below (USD 29.64) |
| MACD | -0.31 (negative) |
Analyst Ratings (IMCR)
Wall Street analysts rate IMCR "Buy" based on 13 analysts, with a mean price target of USD 63.49 (range USD 34–100), per Nexqual as of June 10, 2026 at 03:09 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 63.49 |
| High Target | USD 100 |
| Low Target | USD 34 |
| Buy / Hold / Sell | 11 / 4 / 0 |
Earnings (IMCR)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 0.02 |
| Revenue Estimate | $110.31M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.25 vs est -0.26 ▲ beat |
| 2025-12-31 | USD -0.6 vs est -0.2 ▼ miss |
| 2025-09-30 | USD 0 vs est -0.24 ▲ beat |
| 2025-06-30 | USD -0.2 vs est -0.21 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Financials & Fundamentals (IMCR)
| Total Revenue | $412.81M |
|---|---|
| Revenue Growth (YoY) | +13.60% |
| Gross Margin | +32.28% |
| Operating Margin | +6.82% |
| Profit Margin | -6.68% |
| ROE | -7.14% |
| Debt / Equity | 110.67 |
| Current Ratio | 4.18 |
| Total Cash | $844.90M |
| Total Debt | $435.68M |
| Free Cash Flow | $58.58M |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Financial Health Score (IMCR)
Nexqual rates Immunocore Holdings Plc's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 03:09 UTC.
| Growth | Strong — Revenue +29% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 32%, operating 7% |
| Balance Sheet | Mixed — $845M cash vs $436M debt, net cash position |
| Cash Flow | Solid — FCF $59M, 15% margin |
| Efficiency | Critical — ROE -7%, ROA -0.9% |
Ownership (IMCR)
| Insider Ownership | +0.07% |
|---|---|
| Institutional Ownership | +104.50% |
| Shares Outstanding | 50.87M |
| Float | 42.46M |
| Short % of Float | +19.14% |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
Leadership (IMCR)
Immunocore Holdings Plc is led by Bahija Jallal (age 64), CEO & Executive Director, per Nexqual as of June 10, 2026 at 03:09 UTC.
| CEO & Executive Director | Bahija Jallal (age 64) |
|---|---|
| CFO, Executive VP & Head of Corporate Development | Travis Alan Coy (age 45) |
| Executive VP & Chief Operating Officer | Kripa Ram (age 62) |
| Senior VP, CTO and Research & UK Site Lead | Annelise Vuidepot |
| Vice President of Communications | Sébastien Desprez |
Major Backers & Investors (IMCR)
Notable institutional backers of Immunocore Holdings Plc include RTW Investments LP, FMR, LLC, Wellington Management, according to Nexqual as of June 10, 2026 at 03:09 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RTW Investments LP | 9.57% |
| FMR, LLC | 9.49% |
| Wellington Management | 9.25% |
| Primecap Management Company | 7.26% |
| T. Rowe Price | 5.89% |
| Bellevue Group AG | 5.5% |
| Vestal Point Capital, LP | 5.44% |
| Tang Capital Management, LLC | 5.21% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 11.96% |
Source: Nexqual, June 10, 2026 at 03:09 UTC.
From Immunocore Holdings Plc's Latest SEC 10-K Filing (filed 2026-02-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally.
- The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma.
- In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus.
- Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CGEM | Cullinan Therapeutics, Inc. | USD 13.18 | ▼ 2.44% |
| VOR | Vor Biopharma Inc. | USD 13.28 | ▲ 0.91% |
| DSGN | Design Therapeutics, Inc. | USD 10.55 | ▼ 0.94% |
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| NUVL | Nuvalent, Inc. | USD 123.25 | ▲ 35.51% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:09 UTC. This page is informational and not investment advice.